Mak Capital One led a $19m Series A round in Marabio.

Mak Capital One, the New York-based investment management firm, led a $19m Series A round in Marabio, a precision immunology company. "MAK's investment in MARAbio reflects our conviction in the market potential of their revolutionary blood test. This capital raise will enable the commercialization of a powerful new diagnostic tool to benefit potentially millions of families, pre- and post-pregnancy," Michael A. Kaufman, MAK Capital CEO.